semaglutide for weight loss and alcohol tirzepatide injections Weight-loss drug semaglutide reduces heavy

Accessed June 9, 2026

Benefits Beyond Sugar Management and Weight Loss Current Indications for Semaglutide: Glucose control in adults with type 2 diabetes Reduced risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease Obesity in adults Reduced risk of kidney decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Additional Semaglutide Studies: Reducing fatty liver disease Use in adults and pediatric patients aged 12 years and older with obesity Reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight Semaglutide oral tablets for type 2 diabetes Current Indications for Tirzepatide: Glucose control in adults with type 2 diabetes Obesity in adults, or overweight adults with at least one weight-related comorbidity Moderate to severe obstructive sleep apnea in adults with obesity Additional Tirzepatide Studies: Reducing fatty liver disease Improving osteoarthritis in the knees Use in adolescents with obesity or overweight with weight-related comorbidities Use in people with overweight or obesity and chronic kidney disease with or without type 2 diabetes Both semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are being studied for additional health benefits beyond blood sugar management and weight loss

Specifically, participants who had lost an average of 17.3% of their body weight while on semaglutide regained about 11.6 percentage points, leaving them with only 5.6% net weight loss from baseline

Other notable semaglutide drugs include Rybelsus and Wegovy